REG - Dr. Martens PLC - Director/PDMR Shareholding

Dr MartensAnnouncement

Tue 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nRSB5226Ga&default-theme=true

RNS Number : 5226G  Dr. Martens PLC  02 June 2026

Dr. Martens plc (the 'Company')

Director / PDMR Shareholding

Notification of Transactions by Directors / Persons Discharging Managerial
Responsibility

The Company announces that, on 29 May 2026, the following directors / persons
discharging managerial responsibility ('PDMR') were granted Performance Share
Awards (the 'Awards') under the Company's Long Term Incentive Plan (the
'LTIP').

 

 PDMR          Number of Shares
 Ije Nwokorie  2,732,653
 Giles Wilson  2,100,151

 

The Awards will vest subject to the achievement of three equally weighted
targets, namely cumulative earnings per share, relative total shareholder
return and operating cash conversion, over three years. On vesting, the Awards
will be subject to a further two-year holding period. No consideration was
paid for the grant of the Awards and no price is payable on the exercise of
the Awards.

Full details of the target ranges are set out in the Directors' Remuneration
Report in the 2026 Annual Report & Accounts, which is available on the
Company's website at www.drmartensplc.com.

The relevant notifications set out below are provided in accordance with the
requirements of Article 19 of the UK Market Abuse Regulation.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Ije Nwokorie
 2   Reason for the notification
 a)  Position/status                                              PDMR (Chief Executive Officer)
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Dr. Martens plc
 b)  LEI                                                          213800QPT8YM6NQZPH28
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of GBP 0.01

     Identification code                                          ISIN: GB00BL6NGV24
 b)  Nature of the transaction                                    Grant of performance share award under the Dr. Martens Long Term Incentive
                                                                  Plan
 c)  Price(s) and volume(s)                                           Price(s)  Volume(s)
                                                                    Nil       2,732,653
 d)  Aggregated information

- Aggregated volume

     - Price                                                      2,732,653

                                                            Nil

 
 e)  Date of the transaction                                      29 May 2026
 f)  Place of the transaction                                     Outside of a trading venue

d)

Aggregated information

 -  Aggregated volume
 -  Price

 

 

2,732,653

Nil

e)

Date of the transaction

29 May 2026

f)

Place of the transaction

Outside of a trading venue

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Giles Wilson
 2   Reason for the notification
 a)  Position/status                                              PDMR (Chief Financial Officer)
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Dr. Martens plc
 b)  LEI                                                          213800QPT8YM6NQZPH28
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of GBP 0.01

     Identification code                                          ISIN: GB00BL6NGV24
 b)  Nature of the transaction                                    Grant of performance share award under the Dr. Martens Long Term Incentive
                                                                  Plan
 c)  Price(s) and volume(s)                                           Price(s)  Volume(s)
                                                                    Nil       2,100,151
 d)  Aggregated information

- Aggregated volume

     - Price                                                      2,100,151

                                                            Nil

 
 e)  Date of the transaction                                      29 May 2026
 f)  Place of the transaction                                     Outside of a trading venue

d)

Aggregated information

 -  Aggregated volume
 -  Price

 

 

2,100,151

Nil

e)

Date of the transaction

29 May 2026

f)

Place of the transaction

Outside of a trading venue

 

For further information, please contact:

Paul Rolling, Head of Secretariat

+447584243562

Bethany Barnes, Director of Investor Relations and Corporate Communications

+447825187465

ENDS

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire,
England. Its first silhouette, the 1460 boot - named after the date it was
produced - rolled off the production line on 1st April 1960. Originally chosen
by workers for their air-cushioned comfort and durability, "Docs" or "DM's"
were later adopted by musicians and subcultural pioneers who took them from
the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and
employs around 3,600 people. The company continues to honour the brand's
heritage through its 'Made in England' footwear, manufactured at its original
Northamptonshire factory, while meeting global demand from multiple
high-quality production sites across Asia. All our products are made with an
unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the
crowd, Dr. Martens is available through Direct-to-Consumer (Retail and
Ecommerce) and Wholesale channels. The brand's collections range from its
Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976
Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz,
and Lowell. The lineup also includes an extensive range of sandals, a
dedicated Kids collection, and a curated selection of bags, small leather
goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style,
comfort, and versatility. Having transcended generations, the brand stays as
relevant today as it was at its inception. Its signature yellow welt
stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops
remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock
Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAOSRNRUNRAR



            Copyright 2019 Regulatory News Service, all rights reserved